HIV Dart – presentations

  Welcome session
David Barry DART Achievement Award Lecture: The Discovery of SIV and Development of Monkey Models for the Study of HIV/aids
Dr. R. Desrosiers, University of Miami, USA
  Session 1: Cure Session (Sponsored by amfAR)
Chairs: R. Johnston & R.F. Schinazi
Controversies and Misconceptions in HIV Reservoir Research (not available)
Dr. M. Stevenson University of Miami/GVN, USA
HIV-1 Macrophage Reservoirs: Lessons from Host Macrophage Specific Restriction Factor, SAMHD1
Dr. B. Kim, Emory University, USA
Humanized Mice as Models in Drug Development for Antiviral Therapies (not available)
Dr. J.V. Garcia-Martinez, University of Nebraska Medical Center, USA
Sustained Virologic Control in SIV+ Macaques (not available)
Dr. S. Byrareddy, University of Nebraska Medical Center, USA
  Abstract presentations
 Differential responses of memory CD4+ T cell subsets to HIV latency reversing agents
Dr. D. Kulpa, Emory University, USA
 HIV-1 dynamics under integrase inhibitor therapy suggests a subset of cells with slow integration
Dr. R.M. Ribeiro, Los Alamos National Laboratory, USA
  Session 2: New Drugs for HIV
Chairs: B. Kim & R. C. Desrosiers
Integrase Inhibitors Today and Tomorrow (not available)
Dr. J. Grobler, Merck Inc., USA
Development of a New Class of Allosteric Inhibitors of HIV-1 Integrase with Promising Activity Against Resistance Mutations  (coming soon)
Dr. E. Arnold, Rutgers University, USA
CryoEM Structures and Atomic Model of the HIV-1 Strand Transfer Complex Intasome (coming soon)
Dr. D. Lyumkis, Salk Institute, USA
  Session 3: Inflammation and Cure
Chairs: M. Stevenson & D. Thomas
Current Clinical Therapies for HIV Remission
Dr. D. Margolis, University of North Carolina, USA
Impact of Jak Inhibitors on HIV Reservoir Maintenance, Lifespan and Expansion in Primary T Cells and Macrophages
Dr. C. Gavegnano, Emory University, USA
  Abstract presentations
 Anti–HIV drug candidate abx464 prevents intestinal inflammation by producing IL22 in activated macrophages
Dr. J. Tazi, Laboratoire coopératif ABIVAX-CNRS-UM, USA
  Morning session
Chairs: R. Johnston & C. Boucher
Gertrude Elion Distinguished Lecturer Award Lecture Stories on Scientific Discoveries that Transformed HIV into a Manageable Disease
Dr. M. Wainberg, McGill University, Canada
  Session 4: New Drugs and NeuroAIDS
Chairs: L. Kovari & C. Boucher
Management of Neurocognitive Impairment of Aging Populations Living with HIV
Dr. S. Letendre, University of California, USA
EFdA (4'-Ethynyl-2-fluoro-2'-deoxyadenosine) a Powerful Nucleoside Analog for HIV Infections (not available)
Dr. H. Mitsuya, National Cancer Institute, USA
  Abstract presentations
 Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF)
Dr. B. Baugh, Janssen Research & Development LLC, USA
 Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V
Dr. C. Callebaut, Gilead, USA
  Session 5: Co-infections, Immunology and Public Health
Chairs: R. Schinazi & E. Arnold
Management of HIV/HBV/HCV Coinfections
Dr. D. Thomas, Johns Hopkins School of Medicine, USA
AAV Vector to Deliver Potent Broadly Neutralizing Antibody for Treatment Purpose (not available)
Dr. R.C. Desrosiers, University of Miami, USA
HIV Knowledge and Hope in Africa
Dr. C.A. Harris, Albert Einstein College of Medicine, USA
Phylogenetics and Intervention Strategies (not available)
Dr. R. Harrigan , British Columbia Centre for Excellence in HIV , Canada
  Abstract presentations
 Predicting Antiviral Drug Toxicity Using Contractility Analysis Of Human IPSC Derived Cardiomyocytes
Dr. B.D. Herman, Emory University School of Medicine, USA
  Session 6: Emerging Viruses I: Epidemiology, Pathogenesis & Treatment
Chairs: H. Mitsuya & M. Wainberg
What Do We Really Know About Dengue Viruses 
Dr. P. Perng, National Cheng Kung University, Taiwan
Insights into Viral Pathogenesis and Antiviral Strategies for Zika (not available)
Dr. A. Perelson, Los Alamos, USA
Global Burden and Novel Treatment of Noroviruses
Dr. L. Kovari, Wayne State University, USA
Zika Neuropathies Beyond Microcephaly
Dr. M. Lacerda Nogueira Medicine School of São José do Rio Preto (FAMERP), Brazil
  Abstract presentations
 In Silico Approaches Towards Broadly Active Flavivirus Protease Inhibitors
Dr. B.D. Cox, Emory University, USA
 Jak 1/2 Inhibition Modulates Production of Replication Competent Zika Virus in Primary Human Hofbauer, Trophoblast and Neuroblastoma Cells (coming soon)
Dr. L. Bassit, Emory University, USA
  Session 7: Emerging Viruses II: Diagnosis and Treatment
Chairs: A. Perelson & O. Perng
Research efforts to combat ZIKA: The Miami experience (not available)
Dr. D. Watkins, University of Miami, USA
Zika-Specific Antibodies for Prophylaxis and Detection (not available)
Dr. D. Watkins, University of Miami, USA
Rapid Zika Detection for Resource-Limited Regions
Dr. M. Sharkey, Discidium/University of Miami, USA